Madrigal Pharmaceuticals, Inc.

This study tests a daily pill called resmetirom in about 1,759 adults with NASH, a fatty liver disease that can lead to cirrhosis. The goal is to see if the drug can reverse liver inflammation and scarring, and prevent progression to severe liver disease or death. Participants re…

This study tests a daily pill called resmetirom in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it safely reduces liver fat and cholesterol over 52 weeks. About 810 adults who completed earlier related studies are taking part. This is a long-term t…

This study tests whether a daily pill called resmetirom can prevent serious liver problems in people with NASH-related cirrhosis (scarring of the liver). About 845 adults with well-compensated cirrhosis (still functioning liver) will receive either the drug or a placebo for sever…